Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated split influenza virus haemagglutinin
- Development stage
- Unknown
- Lead developer
- Vaxxas
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal
01
Overview
Inactivated split influenza virus haemagglutinin is a monovalent vaccine antigen derived from the A/Singapore/GP1908/2015 (H1N1) strain (A/Michigan/45/2015-like). Developed by Vaxxas, this antigen is specifically designed for delivery via the company's proprietary High-Density Microarray Patch (HD-MAP), a transdermal platform featuring thousands of microprojections that deposit the vaccine into the immune-cell-rich layers of the skin (dermis and epidermis). The antigen targets the influenza haemagglutinin (HA) surface glycoprotein to elicit protective immune responses, including haemagglutination inhibition (HAI) and microneutralisation (MN) antibodies. Clinical studies have demonstrated significant dose-sparing potential, with low doses delivered via HD-MAP achieving comparable immunogenicity to standard intramuscular injections.
- Other names
- influenza virus haemagglutinin (inactivated split)monovalent split inactivated influenza virus vaccine antigen
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on inactivated split influenza virus haemagglutinin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated split influenza virus haemagglutinin.